American College of Cardiology

BRAUNWALD ET AL., MANAGEMENT OF PATIENTS WITH UNSTABLE ANGINA AND NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UPDATE
http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm

ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)

Figure 8. Summary of trials of antithrombotic therapy in UA. Meta-analysis of randomized trials in UA/NSTEMI that have compared ASA with placebo, the combination of UFH and ASA with ASA alone, the combination of an LMWH and ASA with ASA alone, and the combination of a platelet GP IIb/IIIa antagonist (anta.), UFH (hep.), and ASA with UFH plus ASA. The RR values, 95% CIs, and probability value for each trial are shown. The timing of the end point (death or MI) varied. Results with the platelet GP IIb/IIIa antagonists are reported at the 30-day time point. Incremental gain is observed from single therapy with ASA to double therapy with ASA and UFH and to triple antithrombotic therapy with ASA, UFH, and a platelet GP IIb/IIIa antagonist. In the CAPTURE trial, nearly all patients underwent PCI after 20 to 24 h per study design. From PURSUIT ⁽¹⁰⁾, PRISM-PLUS ⁽²¹⁾, Lewis et al. ⁽¹⁷⁵⁾, Cairns et al. ⁽¹⁷⁶⁾, Théroux et al. ⁽¹⁷⁷⁾, RISC group ⁽¹⁷⁸⁾, ATACS group ⁽¹⁷⁹⁾, Gurfinkel et al. ⁽¹⁸⁰⁾, FRISC group ⁽¹⁸¹⁾, CAPTURE ⁽¹⁸²⁾, PARAGON ⁽¹⁸³⁾, and PRISM ⁽¹⁸⁴⁾.